Company intelligence / Profile preview

BioSentinel

Madison, Wisconsin, United Statesbiosentinelpharma.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

BioSentinel develops rapid, sensitive, animal-free assays for the detection and quantification of botulinum neurotoxins. Their products set new standards in speed and sensitivity compared to traditional mouse bioassays. The company’s technologies are used by pharmaceutical companies for quality control of BoNT drugs as well as by government agencies for biodefense[1][2][5].

Modalities: AssayDiagnostic kit
Industry: Non-Drug Biotech

Partnerships

National Wildlife Health CenterUS Army Medical Research Institute of Chemical DefenseUniversity of Wisconsin-MadisonPrivate sector partners in technology development

Beyond the preview

Go deeper on BioSentinel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSentinel.

Explore the full profile